Good afternoon and welcome to The Beauty Health Company Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I would like now to turn the conference over to [Norberto Aja], Investor Relations. Please go ahead.

Thank you, operator and good afternoon, everyone. Thank you for joining us today to discuss The Beauty Health Company's third quarter 2023 financial results, which were released this afternoon and can be found on our website at beautyhealth.com. With me today are Beauty Health's Board Member and incoming Interim Chief Executive Officer; Marla Beck and Chief Financial Officer, Mike Monahan. Today's call will not include a Q&A session, though management will be available afterwards for any follow-up questions you may have. Before we begin, I would like to remind you of the company's Safe Harbor language. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements that are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. Listeners are cautioned not to place undue reliance on any forward-looking statements. For a further discussion of risks related to our business, please see our filings with the SEC. This call will present non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP measures can be found in our earnings press release filed with the SEC today and available on our website. With that, I would now like to turn the call over to Marla. Please go ahead. Thank you, Norberto, and thank you, everyone, for joining us on the call today. Before I start, on behalf of the Board, I would like to thank Andrew for his leadership and commitment to Beauty Health. I look forward to partnering closely with him during this transition period. I'm excited to join Beauty Health as the Interim CEO. For those of you who do not know me, I've spent my entire career in the beauty and wellness space, notably as CEO of Bluemercury for 22 years. I founded Bluemercury in 1999 and…

Thank you, Marla, and thank you, everyone, for joining us today. I also want to thank Andrew for his service. Even though we have only worked together for a short time, I came to know him as a passionate and dedicated leader and wish him the best in the future. Today, we released a significant amount of information, so I'd like to state a few things upfront. First, our recent financial performance is not acceptable. The Board and management are committed to delivering future value for our shareholders and have taken steps to position the company for long-term future success. Second, we did not take the decision to impair our earlier generation delivery systems lightly. Our long-standing provider relationships play a critical role in our continued success. Nearly half of the devices we sold in the past nine to 11 years are still active. Providing reliable products and services is always our primary goal and the decisions we made this quarter protect our customers and the Hydrafacial brand. Third, our recent performance is largely a result of provider experience issues with Syndeo in the U.S. We have taken the learnings to avoid any similar issues in the future. We want to be very clear that the impact applies only to providers who use Syndeo 1.0 or 2.0 delivery systems. There was no impact on the safety or efficacy of the Hydrafacial treatment. We believe our latest generation; Syndeo 3.0 provides the best experience for our providers. Fourth, we believe the fundamentals of our business and future opportunity remains strong. The issues we face are executional in nature, not strategic. On the system side, it's important to highlight that our products are excessively priced relative to other medical devices, lowering the barrier to entry for providers. In addition, the economics of…

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.